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Summary
AIMS OF THE STUDY: The prevalence of the use of val-
proate during pregnancy and by women of childbearing
age in Switzerland is not known. We aimed to study the
use of antiseizure drugs by these women in Switzerland,
with a particular focus on valproate.
METHODS: We conducted a retrospective descriptive
study using the healthcare claims database of the Swiss
health insurance Helsana (2014–18). We established two
separate study populations: (1) a cohort of pregnancies
leading to a delivery, and (2) all women of childbearing age
(15–45 years) who were insured with Helsana for at least
one year during the study period. We identified the dispen-
sation of valproate, lamotrigine, carbamazepine, levetirac-
etam, topiramate, pregabalin, gabapentin, phenobarbital,
and phenytoin (1) between delivery and three months prior
to the estimated date of the last menstrual period, and (2)
by calendar year. We quantified exposure prevalence of
each antiseizure drug as the number of women with ≥1
prescription fill per 10,000 (1) pregnancies, and (2) women
by calendar year. Results were weighted for the demo-
graphic distribution of the Helsana population relative to
the Swiss population.
RESULTS: We identified a weighted pregnancy population
of 387,418 pregnancies, with a mean maternal age at de-
livery of 31.9 years (standard deviation 5.1). Lamotrigine
was the most frequently dispensed antiseizure drug dur-
ing pregnancy (20/10,000), followed by levetiracetam (11/
10,000), and pregabalin (3.8/10,000). Valproate was dis-
pensed to 1.9/10,000 women during pregnancy and to 1.3/
10,000 women within 90 days prior to the last menstru-
al period but not during pregnancy. The weighted study
population of women aged 15–45 years consisted of
2,781,151 women, of whom 74,080 (270/10,000) were ex-
posed to ≥1 of the evaluated antiseizure drugs. Pregabalin
was the most frequently dispensed antiseizure drug (64/
10,000), followed by lamotrigine (46/10,000), topiramate
(32/10,000), and valproate (25/10,000). The use of val-
proate decreased from 28/10,000 women in 2014 to 21/
10,000 women in 2018.
CONCLUSIONS: The prevalence of exposure to valproate
during pregnancy was comparable to Denmark and lower
than in other European countries. Despite decreasing ex-
posure prevalence, the use of valproate in women of child-
bearing age in Switzerland seems higher than the actual
clinical need.
Keywords: valproic acid, valproate, antiseizure drugs,
Switzerland, claims database, pregnancy, women of child-
bearing age, drug utilisation, electronic database, pharma-
coepidemiology
Introduction
Valproate has been available in Switzerland since 1972 for
the treatment of epilepsy, and since the mid-1990s also for
bipolar disease [1]. Since the 1980s, a congenital valproate
syndrome has been characterised, which occurs in up to
10% of children after in utero exposure to valproate during
the first trimester [2]. The syndrome comprises neural tube
defects, cardiovascular anomalies, limb defects, hypospa-
dias, oral clefts, and dysmorphic facial features [3–6]. In
the early and mid-2000s, case series described develop-
mental delays in children with in utero valproate expo-
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sure [7–9]. In 2009, a prospective cohort study, including
309 children exposed in utero to antiseizure drugs, report-
ed significantly lower mean cognitive test scores at 3 years
of age in 96 children with valproate exposure when com-
pared to children exposed to lamotrigine, carbamazepine,
or phenytoin [10]. Since then, several observational studies
substantiated these findings, consistently reporting an in-
creased risk of autism, attention deficit hyperactivity dis-
orders, decreased cognitive function, and learning difficul-
ties in children after in utero valproate exposure [10–17].
Some studies suggest that the risk of developmental disor-
ders may be as high as 30–40% for children with in utero
exposure to high doses of valproate [18].
The US Food and Drug Administration (FDA) issued a
warning in 2011 [19], followed by the European Medicines
Agency (EMA) in 2014 [20] and Swissmedic in 2015 [21].
They advised that valproate should not be used during
pregnancy or by women of childbearing age unless other
substances are ineffective or not tolerated. Since 2015, an
increasingly heated public debate has unfolded, first in
France, and then in Switzerland and other European coun-
tries, about whether or not authorities issued sufficiently
appropriate and timely warnings. Until today, the number
of exposed pregnant women in Switzerland, and thus the
estimated number of affected children, remains unknown.
We conducted an observational study using the Helsana
claims database to quantify the number of prescriptions
of valproate and other antiseizure drugs filled by pregnant




We conducted a retrospective descriptive study using the
healthcare claims database of the Swiss health insurance
Helsana for the years 2014-18. The Helsana group is one
of Switzerland’s leading health insurance companies, cov-
ering 1.1 million individuals with mandatory health insur-
ance from all 26 cantons (approximately 15% of the Swiss
population). The database includes information on inpa-
tient and outpatient healthcare services, including drug dis-
pensations, as well as demographics. For dispensation of
prescription drugs, the corresponding codes of the anatom-
ical therapeutic chemical (ATC) classification system are
available [22]. All data are anonymous, and all analyses
were conducted internally by the department of health sci-
ences of the Helsana group.
Pregnancy cohort
Identification of delivery date
We identified inpatient and outpatient deliveries (including
live births and stillbirths) covered by mandatory health in-
surance in the Helsana claims database between January
2014 and December 2018. Inpatient deliveries were
recorded by means of SwissDRG (Drug Related Diagno-
sis) codes, and outpatient deliveries by means of Tarmed
codes or billed deliveries by midwifes (appendix 1, see
separate PDF file for download). Delivery codes recorded
within a period of 30 days were regarded as pertaining to
the same pregnancy [23], and the date of delivery was de-
fined as the first recorded code. Delivery codes separated
by more than 300 days were considered as two separate
pregnancies (fig. 1). When two subsequent codes were sep-
arated between 30 to 300 days, the date of delivery was set
at the inpatient SwissDRG code, whereas women (n = 80
women) were excluded if no SwissDRG code was record-
ed. We excluded pregnancies during which women were
not continuously covered by mandatory insurance at Hel-
sana between their last menstrual period and delivery (n
= 9166 pregnancies). Some women contributed more than
one pregnancy to the cohort. Twins were treated as single
births.
Identification of the date of the last menstrual period and
pregnancy trimesters
The date of the last menstrual period (i.e., start of preg-
nancy) was estimated, because gestational length or start of
pregnancy are not recorded in healthcare claims data. Ac-
cording to an algorithm validated in US claims data [19],
the date of the last menstrual period was assigned to be 245
days before the date of delivery for pregnancies that had
a DRG code indicative of preterm delivery (<37 weeks,
O01A, O01B, O01C, O01D, O60A), and 270 days before
the date of delivery for all other pregnancies. A pregnan-
cy trimester was defined to be 90 days, whereby the third
trimester was shortened in case of a preterm delivery (fig.
1).
Cohort of women of childbearing age
The cohort of women of childbearing age included all
women aged 15-45 years between 2014 and 2018, irrespec-
tive of whether they were pregnant or not. Women were
eligible to contribute data to any given year if they were
continuously insured with Helsana’s mandatory health in-
surance for the entire year (January–December).
Figure 1: Definition of delivery and last menstruation period (LMP) scheme.
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Covariates and descriptive analyses
For all pregnancies, we captured maternal age at delivery,
the year of delivery, and whether the recorded codes
(SwissDRG and Tarmed) indicated a caesarean section.
For women of childbearing age, we captured age in the
year of interest and the year the drug was dispensed.
Antiseizure drugs were identified based on recorded ATC
codes of recorded prescription fills of drugs in claims data,
and included valproate (N03AG01), lamotrigine
(N03AX09), carbamazepine (N03AF01), levetiracetam
(N03AX14), topiramate (N03AX11), pregabalin
(N03AX16), gabapentin (N03AX12), phenobarbital
(N03AA02), and phenytoin (N03AB02). Due to the data
structure of electronic claims data, we were not able to take
into account the indication for the use of individual anti-
seizure drugs. We quantified the prevalence of prescrip-
tion fills for specific antiseizure drugs in both cohorts, de-
fined as women/pregnancies, with ≥1 recorded claim for
an antiseizure drug divided by the total number of en-
rolled women/pregnancies during the respective time peri-
od. Prevalence of antiseizure drug exposure is presented as
absolute numbers per 10,000 women/pregnancies by cal-
endar year. In women of childbearing age, prevalence of
antiseizure drug exposure is also presented by age groups.
For the pregnancy cohort, we further categorised whether
the last valproate prescription was filled between the date
of the last menstrual period and delivery, or within 90 days
before the last menstrual period (discontinuers), excluding
pregnancies with less than 90 days of enrolment before the
last menstrual period.
We weighted results of both cohorts, accounting for the
demographic distribution of the population insured with
mandatory insurance with Helsana relative to the Swiss
population. Weighting factors included calendar year, can-
ton, age, and sex. Because sample size was small, absolute
numbers of women/pregnancies exposed to specific anti-
seizure drugs are not shown to preserve patient confiden-
tiality. In order to focus on the relevant antiseizure drugs
with regard to prescription frequency, only antiseizure
drugs with a minimum weighted prevalence of 50 exposed
pregnancies are presented. All analyses were conducted
using the statistical programming language R (R version
3.6.1).
Protocol approvals
This retrospective observational study using anonymous
data did not require an ethics committee approval.
Results
Pregnancy cohort
Between January 2014 and December 2018, we identified
a weighted population of 387,418 pregnancies leading to
a delivery. The mean age at delivery ranged between 31.8
(standard deviation 5.1) and 32.1 (standard deviation 5.0)
years between 2014 and 2018 (table 1). Of those, between
24,832 (33.0%) and 27,392 (33.5%) deliveries were cae-
sarean sections, which is in accordance with data of the
Swiss federal statistical office [24].
After weighting, valproate was dispensed during 1.9/
10,000 pregnancies between 2014 and 2018. Overall, val-
proate was less frequently dispensed during pregnancy
than other antiseizure drugs. Lamotrigine was the most
frequently dispensed antiseizure drug during pregnancy
(20.0/10,000), followed by levetiracetam (11.0/10,000),
and pregabalin (3.8/10,000, table 2, fig. 2). For 1.3/10,000
pregnancies, a valproate prescription was filled within 90
days prior to the last menstrual period but not during preg-
nancy (discontinuers). The prevalence of antiseizure drug
exposure in the unweighted pregnancy population is not
shown for confidentiality reasons.
Table 1: Demographics of the weighted pregnancy population (2014–18)
2014 2015 2016 2017 2018
No. of pregnancies 75,462 76,321 78,609 81,888 75,137
Mean age at delivery in years (standard deviation) 31.8 (5.1) 31.9 (5.2) 31.8 (5.2) 32.0 (5.2) 32.1 (5.0)
<20 years 446 (0.6%) 389 (0.5%) 479 (0.6%) 354 (0.4%) 376 (0.5%)
20–25 years 8279 (11%) 8599 (11.3%) 8345 (10.6%) 8324 (10.2%) 6938 (9.2%)
26–30 years 21,082 (27.9%) 21,286 (27.9%) 22,487 (28.6%) 23,113 (28.2%) 21,232 (28.3%)
31–35 years 27,654 (36.6%) 27,360 (35.8%) 28,480 (36.2%) 29,612 (36.2%) 27,686 (36.8%)
36–40 years 14,836 (19.7%) 15,215 (19.9%) 15,374 (19.6%) 16,596 (20.3%) 15,725 (20.9%)
41–45 years 3000 (4.0%) 3246 (4.3%) 3166 (4.0%) 3572 (4.4%) 2931 (3.9%)
>45 years 165 (0.2%) 225 (0.3%) 278 (0.4%) 318 (0.4%) 250 (0.3%)
Caesarean section 25,983 (34.4%) 26,177 (34.3%) 26,200 (33.3%) 27,392 (33.5%) 24,832 (33.0%)
Table 2: Weighted prevalence of exposure to antiseizure drugs (per 10,000) during pregnancy (2014–18)
Valproate Lamotrigine Carbamazepine Levetiracetam Topiramate Pregabalin
Exposed pregnancies
(per 10,000)
1.9 20.0 3.0 11.0 2.4 3.8
Discontinuers* 1.3 0.7 0.4 0.8 3.3 9.3
Exposed pregnancies by year
2014 NA† 20.0 3.8 10.0 2.9 2.7
2015 3.8 18.0 3.4 12.0 5.2 5.6
2016 2.2 18.0 2.4 7.0 0.9 3.2
2017 2.6 22.0 0.4 13.0 1.3 2.3
2018 1.1 20.0 0.1 10.0 1.9 5.6
* ≥1 filled prescription between 90 days before the last menstrual period and the last menstrual period, but none during pregnancy. † No information available as the cell contained
a 0 in the Helsana cohort.
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Cohort of women of childbearing age
The weighted study population of women aged 15–45
years consisted of 2,781,151 women, of whom 74,080
(2.66%) were exposed to at least one of the evaluated an-
tiseizure drugs during the study period. Pregabalin was the
most frequently dispensed antiseizure drug in women of
childbearing age, with an exposure prevalence of 59-67/
10,000 women, followed by lamotrigine (44–49/10,000),
and topiramate (31–32/10,000). Valproate was the fourth
most frequently dispensed antiseizure drug; 28/10,000
women filled ≥1 prescription in 2014, decreasing to 21/
10,000 women in 2018 (absolute decrease −25%). The
likelihood of filling at least one valproate prescription in-
creased with increasing age, from 24/10,000 women aged
20–25 years to 44/10,000 women aged 41–45 years (table
3, fig. 2). The prevalence of antiseizure drug exposure in
the unweighted population of women of childbearing age
is not shown for confidentiality reasons.
Discussion
We estimated that approximately 1.9/10,000 pregnancies
were exposed to valproate between 2014 and 2018 in
Switzerland. Valproate exposure among women of child-
bearing age was more than 10-fold higher during the same
time period, and decreased from 28/10,000 in 2014 to 21/
10,000 women in 2018.
Our results are consistent with a reported valproate expo-
sure of 2/10,000 pregnancies in Denmark in 2016 [25].
Contrary to the Danish study, however, our results are
based on a relatively small sample of the Swiss population
(15%), and thus our estimates may be subject to variability
introducing some uncertainty. Reported prevalence of in
utero valproate exposure vary by country and region; the
Italian region of Tuscany reported that 15/10,000 pregnan-
cies were exposed to valproate between 2007 and 2016
[26]. The French national agency of drug safety revealed
a valproate exposure prevalence of 25/10,000 pregnancies
in 2007, which declined to 14/10,000 pregnancies in 2014,
and to 3/10,000 pregnancies in 2018 [27, 28], based on an
Figure 2: Prevalences of antiseizure drugs in pregnant women and women of childbearing age.
Table 3: Weighted prevalence of exposure to antiseizure drugs (per 10,000) in women of childbearing age (2014–18).
Valproate Lamotrigine Carbamazepine Levetiracetam Topiramate Pregabalin
Exposure prevalence (/10,000 women) by year
2014 (N women total
= 1,591,025)
28.0 44.0 13.0 17.0 32.0 59.0
2015 (N women total
= 1,598,009)
27.0 45.0 11.0 19.0 32.0 63.0
2016 (N women total
= 1,608,054)
24.0 44.0 10.0 19.0 32.0 67.0
2017 (N women total
= 1,610,897l)
24.0 49.0 10.0 21.0 32.0 67.0
2018 (N women total
= 1,601,858)
21.0 48.0 9.0 19.0 31.0 66.0
Exposure prevalence (/10,000 women) by age
≤20 11.0 22.0 3.6 13.0 23.0 23.0
21–25 24.0 48.0 5.1 24.0 46.0 54.0
26–30 27.0 58.0 10.0 25.0 47.0 76.0
31–35 31.0 63.0 17.0 28.0 50.0 109.0
36–40 36.0 58.0 16.0 21.0 54.0 155.0
41–45 44.0 64.0 23.0 21.0 63.0 232.0
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analysis of national claims data. However, an EMA fund-
ed study suggested that valproate exposure prevalence in
France was lower (11/10,000 pregnancies) as of 2011 [26].
Both the UK and the Emilia-Romagna region in Italy re-
ported valproate exposure in 5/10,000 pregnancies in 2008
and 15/10,000 pregnancies in 2016 [26].
Characteristics of Swiss billing codes did not allow inclu-
sion of pregnancies that ended in termination or abortion
into our study population. (This was the same for the stud-
ies from Denmark and Emilia-Romagna. In France, 38%
of valproate exposed pregnancies accounted for termina-
tions and abortions in 2013 [27], rising to 50% in 2018
[28], which is more than two-fold higher compared to the
reported number of terminations and abortions reported for
the overall French population [29]. It is unclear to what ex-
tent these numbers are applicable to the Swiss population,
but it is likely that (elective) pregnancy terminations and
abortions are also proportionally more frequent among val-
proate users than in the overall Swiss population [30].
In the study population of women of childbearing age,
between 28/10,000 and 21/10,000 women in Switzerland
filled at least one prescription for valproate per year be-
tween 2014 and 2018. Analyses of national claims data re-
vealed a similar prevalence of valproate exposure among
women of childbearing age for Denmark (21-19/10,000
women between 2001 and 2016) [25], Germany (30-25/
10,000 women between 2004 and 2016) [31], Ireland
(35-31/10,000 between 2008 and 2013) [32], and a higher
prevalence for Finland (50-40/10’000 between 2012 and
2016) and France (75-25/10,000 between 2007-2018)
[33,34].
The exact number of women of childbearing age who re-
quire valproate for seizure control in Switzerland is not
known, but it has been shown that between 5-15% of
women with idiopathic (genetic) generalised epilepsy do
not achieve seizure control with antiseizure drugs other
than valproate [35,36]. Other forms of epilepsy, bipolar
disease, and other off-label indications such as migraine
prophylaxis, should not be treated with valproate in this pa-
tient population. Based on data from other European coun-
tries, we estimate that between 0.3-1.5/10,000 pregnancies
and between 0.3-1.7/10,000 women of childbearing age
absolutely require valproate for seizure control (calcula-
tions in appendix 2, see separate PDF file for download).
Small sample size of pregnancies exposed to valproate
in our study population, and several assumptions under-
lying our estimation of women absolutely requiring val-
proate, prevents a conclusion on whether or not valproate
was prescribed too often in Switzerland during pregnan-
cy. However, the more than 10-fold higher prevalence of
valproate exposure among women of childbearing age ob-
served suggests that despite decreasing exposure preva-
lence, valproate is still prescribed to women for whom al-
ternative drug treatment may exist. This is critical, since
studies from US epilepsy registers have reported that up to
65% of pregnancies among women with epilepsy are un-
planned [37]. We do not have information on birth control
use in Swiss claims data, but given that for approximately
1.3/10,000 pregnancies the last valproate prescription was
filled within 90 days before the last menstrual period, preg-
nancies seem to be unplanned in a large proportion of val-
proate users in Switzerland. Ideally, treatment switch to a
new antiseizure drug should be completed a year before the
last menstrual period to allow for a seizure-free year before
conception [38].
In Switzerland, several media reports escalated public at-
tention on children who had developed birth defects after
in utero valproate exposure. This attention increased un-
certainty among patients and healthcare providers and was
driven by a lack of reliable data and subsequent specula-
tions on the magnitude of the problem. Swissmedic con-
cluded that valproate exposure in pregnant women has
been low over the last two decades, based on the observa-
tion that only 29 cases of congenital malformations, and
10 cases of developmental disorders, had been reported to
the Swiss spontaneous reporting system between 1994 and
2019 [21]. However, such systems do not capture drug ex-
posure, and are highly susceptible to underreporting and
bias. Rarely more than 10% of adverse drug events are re-
ported, and the underreporting is especially pronounced if
the events develop slowly (e.g., developmental disorders),
or if the drug has been on the market for a long time [39].
In Switzerland, healthcare claims data are underused on an
institutional level, and drug utilization on a national lev-
el is largely unknown. Other western countries, such as all
Scandinavian countries, France, Germany, and the United
States, have used healthcare claims data for surveillance of
drug use and safety for decades, enhancing them with ex-
ternal data to study vulnerable populations such as preg-
nant women [40–43]. The Swiss federal council's health
policy strategy 2020–2030 declared that the technological
and digital transformation of the healthcare sector was one
of its four main goals in order to improve public health
over the next decade [44]. We hope that our study stimu-
lates the discussion on how to make better use of existing
data sources on an institutional level for the greater good
of the Swiss population, and especially for vulnerable pa-
tient groups such as pregnant women.
Besides the strengths of this study, some limitations need
to be considered. First, due to the claims data from 2019
being incomplete, the observational period ends in 2018;
accordingly, we could not evaluate the effectiveness of
the comprehensive ‘pregnancy prevention program’ for
women treated with valproate, which has been implement-
ed by EMA and Swissmedic in 2018 [45]. Second, health-
care claims data do not provide information on whether or
not all tablets of a filled prescription were taken. We are
therefore unable to evaluate how many of the women who
filled a prescription for valproate within 90 days before the
last menstrual period stopped the drug before conception,
and how many still took it during the first most vulnerable
weeks of pregnancy. Third, we were not able to evaluate
the indication for the use of antiseizure drugs in this study.
It is likely that the majority of women using pregabalin and
topiramate did not have an underlying epilepsy diagnosis,
but used these drugs for neuropathic pain and migraine re-
spectively. Fourth, results have to be interpreted carefully,
as they were estimated based on 15% of the Swiss popula-
tion from all parts of the country with mandatory health in-
surance insured with Helsana, and weighted based on spe-
cific demographic factors. Thus, reported numbers do not
necessarily represent the exact true exposure prevalence in
the overall Swiss population of pregnant women or women
of childbearing age. Fifth, given the descriptive nature of
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this study, we did not perform an a priori sample size cal-
culation. However, results have to be interpreted carefully
given the small sample size of women exposed to certain
antiseizure drugs, and further studies should aim to repli-
cate our results using different data sources. Sixth, as char-
acteristics of Swiss billing codes did not allow inclusion
of pregnancies which ended in termination or abortion in-
to our study population, our prevalence of use is underes-
timated. The underestimation range is however difficult to
predict, as the prevalence of terminations and spontaneous
abortions in Switzerland is unknown.
In conclusion, the prevalence of valproate exposure in
pregnancy was comparable to Denmark, and lower than
in other European countries. As in most other European
countries, the use of valproate in women of childbearing
age between 2014 and 2018 was higher than what we es-
timated to be indicated. This study demonstrates the val-
ue of electronic claims databases in the evaluation of drug
exposure during pregnancy. Future projects are needed to
systematically monitor utilisation of drugs using health-
care claims data, especially in vulnerable patient popula-
tions such as pregnant women. Results of such projects
may build the basis for interventions to increase drug safe-
ty in the pregnant women in Switzerland.
Disclosure statement
This study has been supported by the Swiss RBP IV fund for health
quality and patient safety.
References
1 Heilmittelinstitut SS. Product Information Depakine (R) [Internet]. 2020
[cited 2020 Jan 13]. Available from: https://www.dopps.org/dpm/DPM-
SlideBrowser.aspx?type=ComGrp&id=1
2 Robert E, Guibaud P. Maternal valproic acid and congenital neural tube
defects. Lancet. 1982;2(8304):937. doi: http://dx.doi.org/10.1016/
S0140-6736(82)90908-4. PubMed.
3 Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes
AM, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med.
2001;344(15):1132–8. doi: http://dx.doi.org/10.1056/NE-
JM200104123441504. PubMed.
4 Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, et al.; EU-
ROCAT Antiepileptic Study Working Group. Valproic acid monothera-
py in pregnancy and major congenital malformations. N Engl J Med.
2010;362(23):2185–93. doi: http://dx.doi.org/10.1056/NEJ-
Moa0907328. PubMed.
5 Hernández-Díaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby
M, et al.; North American AED Pregnancy Registry; North American
AED Pregnancy Registry. Comparative safety of antiepileptic drugs dur-
ing pregnancy. Neurology. 2012;78(21):1692–9. doi: http://dx.doi.org/
10.1212/WNL.0b013e3182574f39. PubMed.
6 Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A.
Pregnancy outcome after in utero exposure to valproate : evidence of
dose relationship in teratogenic effect. CNS Drugs. 2008;22(4):325–34.
doi: http://dx.doi.org/10.2165/00023210-200822040-00004. PubMed.
7 Adab N, Kini U, Vinten J, Ayres J, Baker G, Clayton-Smith J, et al. The
longer term outcome of children born to mothers with epilepsy. J Neurol
Neurosurg Psychiatry. 2004;75(11):1575–83. doi: http://dx.doi.org/
10.1136/jnnp.2003.029132. PubMed.
8 Adab N, Jacoby A, Smith D, Chadwick D. Additional educational needs
in children born to mothers with epilepsy. J Neurol Neurosurg Psychia-
try. 2001;70(1):15–21. doi: http://dx.doi.org/10.1136/jnnp.70.1.15.
PubMed.
9 Gaily E, Kantola-Sorsa E, Hiilesmaa V, Isoaho M, Matila R, Kotila M,
et al. Normal intelligence in children with prenatal exposure to carba-
mazepine. Neurology. 2004;62(1):28–32. doi: http://dx.doi.org/10.1212/
WNL.62.1.28. PubMed.
10 Meador K, Baker G, Browning N, Clayton-Smith J, Combs-Cantrell D,
Cohen M, et al. Cognitive Function at 3 Years of Age after Fetal Expo-
sure to Antiepileptic Drugs. N Engl J Med. 2008;359(16):1543–54.
PubMed.
11 Bromley R, Weston J, Adab N, Greenhalgh J, Sanniti A, McKay AJ, et
al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes
in the child. Cochrane Database Syst Rev. 2014;2014(10):CD010236.
doi: http://dx.doi.org/10.1002/14651858.CD010236.pub2. PubMed.
12 Gerard E, Meador K. An Update on Maternal Use of Antiepileptic Med-
ications in Pregnancy and Neurodevelopment Outcomes. J Pediatr
Genet. 2015;04(02):094–110.
13 Baker GA, Bromley RL, Briggs M, Cheyne CP, Cohen MJ, García-
Fiñana M, et al.; Liverpool and Manchester Neurodevelopment Group.
IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled
cohort study. Neurology. 2015;84(4):382–90. doi: http://dx.doi.org/
10.1212/WNL.0000000000001182. PubMed.
14 Christensen J, Pedersen L, Sun Y, Dreier JW, Brikell I, Dalsgaard S. As-
sociation of Prenatal Exposure to Valproate and Other Antiepileptic
Drugs With Risk for Attention-Deficit/Hyperactivity Disorder in Off-
spring. JAMA Netw Open. 2019;2(1):e186606. doi: http://dx.doi.org/
10.1001/jamanetworkopen.2018.6606. PubMed.
15 Meador KJ, Baker GA, Browning N, Cohen MJ, Clayton-Smith J,
Kalayjian LA, et al.; NEAD Study Group. Foetal antiepileptic drug ex-
posure and verbal versus non-verbal abilities at three years of age. Brain.
2011;134(Pt 2):396–404. doi: http://dx.doi.org/10.1093/brain/awq352.
PubMed.
16 Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Ped-
ersen LH, et al. Prenatal valproate exposure and risk of autism spectrum
disorders and childhood autism. JAMA. 2013;309(16):1696–703. doi:
http://dx.doi.org/10.1001/jama.2013.2270. PubMed.
17 Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-
Smith J, et al.; NEAD Study Group. Fetal antiepileptic drug exposure
and cognitive outcomes at age 6 years (NEAD study): a prospective ob-
servational study. Lancet Neurol. 2013;12(3):244–52. doi:
http://dx.doi.org/10.1016/S1474-4422(12)70323-X. PubMed.
18 Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J. Neurode-
velopment of children exposed in utero to lamotrigine, sodium valproate
and carbamazepine. Arch Dis Child. 2011;96(7):643–7. doi:
http://dx.doi.org/10.1136/adc.2009.176990. PubMed.
19 FDA Drug Safety Communication. Children born to mothers who took
Valproate products while pregnant may have impaired cognitive devel-




20 Agency EM. CMDh agrees to strengthen warnings on the use of val-
proate medicines in women and girls [Internet]. 2014 [cited 2020 Jan
14]. Available from: https://www.ema.europa.eu/en/news/cmdh-agrees-
strengthen-warnings-use-valproate-medicines-women-girls
21 Eidgenossenschaft S. Depakine-Skandal. Untersuchung der Situation in
der Schweiz. Bericht des Bundesrates in Erfüllung des Postulates
18.3092, Sänderätin Maury Pasquier Liliane, 7- März 2018. Bern; 2019.
22 World Health Organization. International Statistical Classification of
Diseases and Related Health Problems, 10th Revision. [Internet]. 2016
[cited 2018 Aug 14]. Available from: http://apps.who.int/classifications/
icd10/browse/2016/en#/.
23 MacDonald SC, Cohen JM, Panchaud A, McElrath TF, Huybrechts KF,
Hernández-Díaz S. Identifying pregnancies in insurance claims data:
Methods and application to retinoid teratogenic surveillance. Pharma-
coepidemiol Drug Saf. 2019;28(9):1211–21. doi: http://dx.doi.org/
10.1002/pds.4794. PubMed.
24 Bundesamt für Statistik. Entbindungen und Gesundheit der Mütter im
Jahr 2017 - Medizinische Statistik der Krankenhäuser | Publikation [In-
ternet]. Medizinische Statistik der Krankenhäuser. 2019. Available from:
https://www.bfs.admin.ch/bfs/de/home/statistiken/gesundheit/gesund-
heitszustand/reproduktive.html
25 Daugaard CA, Sun Y, Dreier JW, Christensen J. Use of antiepileptic
drugs in women of fertile age. Dan Med J. 2019;66(8):1–5. PubMed.
26 Hurault-Delarue C, Morris JK, Charlton R, Gini R, Loane M, Pierini A,
et al.; EUROmediSAFE consortium. Prescription of antiepileptic medi-
cines including valproate in pregnant women: A study in three European
countries. Pharmacoepidemiol Drug Saf. 2019;28(11):1510–8. doi:
http://dx.doi.org/10.1002/pds.4897. PubMed.
27 Sante AN de securite du medicament et des produis de. Etude observa-
tionnelle ANSM-CNAMTS de l ’ exposition à l ’ acide valproïque et ses
dérivés au cours de la grossesse en France. 2016.
28 Agence national de sécurité du médicament et des produits de santé.
Valproate et dérivés : l’exposition des femmes enceintes a fortement
diminué mais persiste - Point d’information [Internet]. 2020 [cited 2020




29 Organisation world health. European Health INformation Gateway,
Abortions per 1000 live births [Internet]. [cited 2020 Feb 4]. Available
Original article Swiss Med Wkly. 2021;151:w20386
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 6 of 7
from: https://gateway.euro.who.int/en/indicators/hfa_586-7010-abor-
tions-per-1000-live-births/visualizations/#id=19681
30 Tomson T, Battino D, Bonizzoni E, Craig JJ, Lindhout D, Perucca E, et
al.; EURAP Study Group. Antiepileptic drugs and intrauterine death: A
prospective observational study from EURAP. Neurology.
2015;85(7):580–8. doi: http://dx.doi.org/10.1212/
WNL.0000000000001840. PubMed.
31 Wentzell N, Haug U, Schink T, Engel S, Liebentraut J, Linder R, et al.
Prescribing valproate to girls and women of childbearing age in Ger-
many: Analysis of trends based on claims data. Bundesgesundheitsblatt -
Gesundheitsforsch - Gesundheitsschutz. 2018;61(8):1022–9.
32 Murphy S, Bennett K, Doherty CP. Prescribing trends for sodium val-
proate in Ireland. Seizure. 2016;36:44–8. doi: http://dx.doi.org/10.1016/
j.seizure.2016.01.019. PubMed.
33 Virta LJ, Kälviäinen R, Villikka K, Keränen T. Declining trend in val-
proate use in Finland among females of childbearing age in 2012-2016 -
a nationwide registry-based outpatient study. Eur J Neurol.
2018;25(6):869–74. doi: http://dx.doi.org/10.1111/ene.13610. PubMed.
34 Démographiques institut national d’études. Population par sexe et âge au
1er janvier [Internet]. [cited 2020 Feb 5]. Available from:
https://www.ined.fr/fr/tout-savoir-population/chiffres/france/structure-
population/population-sexe-ages/
35 Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA,
Chadwick DW, et al.; SANAD Study group. The SANAD study of ef-
fectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine,
or topiramate for treatment of partial epilepsy: an unblinded randomised
controlled trial. Lancet. 2007;369(9566):1000–15. doi: http://dx.doi.org/
10.1016/S0140-6736(07)60460-7. PubMed.
36 Jallon P, Latour P. Epidemiology of idiopathic generalized epilepsies.
Epilepsia. 2005;46(s9, Suppl 9):10–4. doi: http://dx.doi.org/10.1111/
j.1528-1167.2005.00309.x. PubMed.
37 Herzog A. HB M, MacEachern D. Association of Unintended Pregnancy
With Spontaneous Fetal Loss in Women With Epilepsy Findings of the
Epilepsy Birth Control Registry. JAMA Neurol. 2019;76(1):50–5. doi:
http://dx.doi.org/10.1001/jamaneurol.2018.3089. PubMed.
38 Tomson T, Battino D, Bromley R, Kochen S, Meador K, Pennell P, et al.
Executive Summary: Management of epilepsy in pregnancy: A report
from the International League Against Epilepsy Task Force on Women
and Pregnancy. Epilepsia. 2019;60(12):2343–5. doi: http://dx.doi.org/
10.1111/epi.16395. PubMed.
39 Goldman SA. Limitations and strengths of spontaneous reports data.
Clin Ther. 1998;20(Suppl C):C40–4. doi: http://dx.doi.org/10.1016/
S0149-2918(98)80007-6. PubMed.
40 Frank AS, Lupattelli A, Nordeng H. Risk factors for discontinuation of
thyroid hormone replacement therapy in early pregnancy: a study from
the Norwegian Mother and Child Cohort Study and the Medical Birth
Registry of Norway. Acta Obstet Gynecol Scand. 2018;97(7):852–60.
doi: http://dx.doi.org/10.1111/aogs.13339. PubMed.
41 Benevent J, Hurault-Delarue C, Araujo M, Montastruc JL, Lacroix I,
Damase-Michel C. POMME: The New Cohort to Evaluate Long-Term
Effects After Prenatal Medicine Exposure. Drug Saf. 2019;42(1):45–54.
doi: http://dx.doi.org/10.1007/s40264-018-0712-9. PubMed.
42 Innovationasausschuss GB. AMTS in utero - Untersuchung zur
Arzneimitteltherapiesicherheit in der Schwangerschaft basierend auf




43 Platt R, Brown JS, Robb M, McClellan M, Ball R, Nguyen MD, et al.
The FDA Sentinel Initiative - An Evolving National Resource. N Engl J
Med. 2018;379(22):2091–3. doi: http://dx.doi.org/10.1056/NE-
JMp1809643. PubMed.
44 Bundesrat D. Die gesundheitspolitische Strategie des Bundesrates
2020-2030 [Internet]. 2020. Available from: https://www.fda.gov/safety/
fdas-sentinel-initiative/fdas-sentinel-initiative-background
45 Swissmedic. Wichtige Sicherheitsinformationen - Valproat: Risiko kon-
genitaler Missbildungen und Entwicklungsstörungen bei der Exposition






Original article Swiss Med Wkly. 2021;151:w20386
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 7 of 7
